Journal of
Cancer Research and Experimental Oncology

  • Abbreviation: J. Cancer Res. Exp. Oncol.
  • Language: English
  • ISSN: 2141-2243
  • DOI: 10.5897/JCREO
  • Start Year: 2009
  • Published Articles: 56

Full Length Research Paper

Levonorgestrel-releasing intrauterine device for management of tamoxifen-induced menorrhagia in breast cancer patients

Mohamed Anwar El-Nory
  • Mohamed Anwar El-Nory
  • Departments of Obstetrics & Gynecology, Faculty of Medicine, Benha University, Egypt.
  • Google Scholar
Gamal I. El-Habbaa
  • Gamal I. El-Habbaa
  • Departments of Obstetrics & Gynecology, Faculty of Medicine, Benha University, Egypt.
  • Google Scholar
Gamal Ibrahim Rageh
  • Gamal Ibrahim Rageh
  • Departments of General Surgery, Faculty of Medicine, Benha University, Egypt.
  • Google Scholar


  •  Accepted: 12 March 2013
  •  Published: 31 January 2014

References

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L (2007). Hormonal therapies for early breast cancer: Systematic review and economic evaluation. Health Technol. Assess. 11(26):iii-iv, ix-xi, 1-134.

Pubmed

 
Jahanzeb M (2007). Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Clin. Ther. 29(8):1535-1547.
Crossref
 
Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, Howell A (2007). Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial. J. Natl. Cancer Inst. 99(4):272-282.
Crossref
 

Zhou LX, Zhu J, Ding H, Jia CX, Xue SJ, Pan RK (2007). Changes in the sonographic appearance of the endometrium after different premenopausal tamoxifen therapies. Nan Fang Yi Ke Da Xue Xue Bao. 27(8):1227-1229.

Pubmed

 
Nelson AL (2010). Levonorgestrel intrauterine system: A first-line medical treatment for heavy menstrual bleeding. Women's Health (Lond Engl). 6(3):347-356.
Crossref
 

O'Flynn N, Britten N (2004). Diagnosing menstrual disorders: A qualitative study of the approach of primary care professionals. Br. J. Gen. Pract. 54(502):353-358.

Pubmed

 
Istre O, Qvigstad E (2007). Current treatment options for abnormal uterine bleeding: An evidence-based approach. Best Pract. Res. Clin. Obstet. Gynaecol. 21(6):905-913.
Crossref
 
EuroQol Group (1990). EuroQol: A new facility for the measurement of health-related quality of life. Health Policy 16(3):199-208.
Crossref
 
International Committee for Standardization in Hematology (1967). Recommendations for hemoglobinometry in human blood. Br. J. Haematol. 13(4):71-75.
Crossref
 
Siedel J (1984). Improved Ferrozine® based reagent for the determination of serum iron (transferrin iron) without deproteinization. Clin. Chem. 30(6):975.
 
Jacobs A, Path FRC, Warwood MJ (1975). Ferritin in serum. Clinical and biochemical implications. N. Engl. J. Med. 292(18):951-956.
Crossref
 

Küçük T, Ertan K (2008). Continuous oral or intramuscular medroxyprogesterone acetate versus the levonorgestrel releasing intrauterine system in the treatment of perimenopausal menorrhagia: A randomized, prospective, controlled clinical trial in female smokers. Clin. Exp. Obstet. Gynecol. 35(1):57-60.

Pubmed

 
Sayed GH, Zakherah MS, El-Nashar SA, Shaaban MM (2011). A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynaecol. Obstet. 112(2):126-130.
Crossref
 
Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH (2011). Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 83(1):48-54.
Crossref
 
Jensen JT, Nelson AL, Costales AC (2008). Subject and clinician experience with the levonorgestrel-releasing intrauterine system. Contraception 77(1):22-29.
Crossref
 
Zapata LB, Whiteman MK, Tepper NK, Jamieson DJ, Marchbanks PA, Curtis KM (2010). Intrauterine device use among women with uterine fibroids: A systematic review. Contraception 82(1):41-55.
Crossref
 
Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W (2007). Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: Long-term follow-up. Maturitas 57(2):210-213.
Crossref
 
Chan SSC, Tam WH, Yeo W, Yu MMY, Ng DPS, Wong AWY, Kwan WH, Yuen PM (2007). A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG 114(12):1510-1515.
Crossref
 
Kesim MD, Aydin Y, Atis A, Mandiraci G (2008). Long-term effects of the levonorgestrel-releasing intrauterine system on serum lipids and the endometrium in breast cancer patients taking tamoxifen. Climacteric 11(3):252-257.
Crossref
 
Trinh XB, Tjalma WAA, Makar AP, Buytaert G, Weyler J, van Dam PA (2008). Use of the levonorgestrel-releasing intrauterine system in breast cancer patients. Fertil. Steril. 90(1):17-22.
Crossref
 
Qi X, Zhao W, Duan Y, Li Y (2008). Successful pregnancy following insertion of a levonorgestrel-releasing intrauterine system in two infertile patients with complex atypical endometrial hyperplasia. Gynecol. Obstet. Invest. 65(4):266-268.
Crossref
 
Lee SY, Kim MK, Park H, Yoon BS, Seong SJ, Kang JH, Jun HS, Park CT (2010). The effectiveness of levonorgestrel releasing intrauterine system in the treatment of endometrial hyperplasia in Korean women. J. Gynecol. Oncol. 21(2):102-105.
Crossref
 
Koh SCL, Singh K (2010). Levonorgestrel-intrauterine system effects on hemostasis and menstrual blood loss in women seeking contraception. J. Obstet. Gynaecol. Res. 36(4):838-844.
Crossref
 
Heikinheimo O, Inki P, Kunz M, Gemzell-Danielsson K (2010). Predictors of bleeding and user satisfaction during consecutive use of the levonorgestrel-releasing intrauterine system. Hum. Reprod. 25(6):1423-1427.
Crossref